U.S. Professional Services Stock News

NYSE:NREF
NYSE:NREFMortgage REITs

NexPoint Real Estate Finance (NREF) Revenue Jump Tests Bearish Decline Narrative After FY 2025 Results

NexPoint Real Estate Finance (NREF) just wrapped up FY 2025 with Q4 total revenue of US$30.0 million and basic EPS of US$0.67. Trailing twelve month revenue came in at US$157.3 million and EPS at US$4.28. Over the past year, the company has seen revenue move from US$73.1 million to US$157.3 million on a trailing basis, with EPS shifting from US$1.02 to US$4.28. This context allows investors to weigh these results against expectations. With margins running well ahead of the prior year, the...
NasdaqGS:MMYT
NasdaqGS:MMYTHospitality

Is MakeMyTrip (NasdaqGS:MMYT) Pricing Fair After Recent Share Price Slide

If you are wondering whether MakeMyTrip at around US$37.88 is a bargain or just looks cheap, the key question is how its current price compares with its underlying worth. The stock has seen sharp moves recently, with a 3.1% decline over the last 7 days, a 32.3% decline over 30 days, and year to date returns of a 53.7% decline, although the 3 year and 5 year returns sit at 61.7% and 26.6% respectively. This price action comes as MakeMyTrip continues to sit in focus as a Nasdaq listed online...
NasdaqCM:MBIN
NasdaqCM:MBINDiversified Financial

How Record Assets and Better Loan Quality At Merchants Bancorp (MBIN) Has Changed Its Investment Story

In its recent fourth-quarter update, Merchants Bancorp reported revenue, earnings per share, and net interest income above analyst expectations, alongside improved asset quality with criticized and nonperforming loans both reduced. Chairman and CEO Michael F. Petrie also reported that total assets reached a record US$19.40 billion, underscoring management’s confidence in the bank’s growth plans for 2026 and beyond. Next, we’ll examine how Merchants Bancorp’s record asset base and stronger...
NYSE:BBY
NYSE:BBYSpecialty Retail

Potential GameStop Bid Puts Best Buy’s Role And Options In Focus

Speculation has picked up that GameStop could be eyeing Best Buy (NYSE:BBY) for a major acquisition after GameStop management flagged interest in a "very, very, very big" deal. Commentary from GameStop about pursuing efficiency focused acquisitions has put Best Buy back in the spotlight as a potential target. The idea of a tie up between the two specialty retailers is drawing fresh attention to Best Buy's role in consumer electronics and services. Best Buy shares recently closed at $64.31,...
NYSE:PVH
NYSE:PVHLuxury

PVH (PVH) Margin Collapse And One Off Loss Challenge Bullish Earnings Narratives

PVH (PVH) has just wrapped up FY 2026 with fourth quarter revenue of US$2.5 billion and a basic EPS loss of US$3.55, capping a trailing twelve month profile that includes total revenue of US$9.0 billion and basic EPS of US$0.53. Over recent quarters, the company has seen revenue move from US$2.0 billion in Q1 2026 to US$2.5 billion in Q4 2026. Quarterly basic EPS has swung between a loss of US$0.88 and a gain of US$4.66, leaving investors to focus on how thin trailing net margins and that one...
NYSE:MLP
NYSE:MLPReal Estate

Maui Land & Pineapple (MLP) Posts Rare Quarterly Profit Testing Bearish Loss-Making Narrative

Maui Land & Pineapple Company (MLP) opened FY 2025 with mixed quarterly numbers, reporting Q3 revenue of US$4.5 million and basic EPS of US$0.01, set against a trailing 12 month net loss of US$11.3 million on revenue of US$18.3 million. Over recent quarters, revenue has ranged from US$2.6 million to US$5.8 million per quarter, while basic EPS has moved between a loss of US$0.44 and a small profit of US$0.01 as reported for Q3 2025. For investors, the latest figures keep the spotlight on...
NYSE:PRKS
NYSE:PRKSHospitality

How Does the ADA Lawsuit Shape United Parks & Resorts’ (PRKS) Long‑Term Brand and Compliance Strategy?

The U.S. Department of Justice has filed a federal lawsuit against United Parks & Resorts, alleging that its late‑2025 ban on wheeled walkers with seats at SeaWorld and Busch Gardens parks discriminated against guests with disabilities and violated the Americans with Disabilities Act, and is seeking policy changes, damages, civil penalties, and staff training. United Parks & Resorts argues the mobility‑device restrictions were introduced for safety reasons and highlights that it offers...
NYSE:STAG
NYSE:STAGIndustrial REITs

Is STAG Industrial (STAG) Offering Value After Recent Share Price Weakness?

If you are wondering whether STAG Industrial is attractively priced today or whether the market has already factored in the key positives, this article walks through what the current share price might be implying about value. STAG Industrial recently closed at US$36.21, with returns of 0.6% over 7 days, an 8.9% decline over 30 days, a 1.9% decline year to date, and a 4.4% gain over the last year, which can signal shifting views on both growth potential and risk. Recent news coverage around...
NasdaqCM:PHOE
NasdaqCM:PHOEConstruction

Phoenix Asia Holdings (PHOE) Margin Compression Reinforces Bearish Narratives Despite Revenue Growth

Phoenix Asia Holdings (PHOE) has just posted its H1 2026 scorecard, with trailing 12 month revenue of about US$7.4 million and net income of roughly US$1.0 million, translating to EPS of US$0.06, while the latest half year print for H2 2025 showed revenue of US$3.6 million and EPS of US$0.02. Over the last reported halves, the company has seen total revenue move from US$2.8 million in H2 2024 to US$3.8 million in H1 2025 and US$3.6 million in H2 2025, with EPS of roughly US$0.04 in both H2...
NasdaqGS:LAES
NasdaqGS:LAESSemiconductor

SEALSQ (LAES) Heavy 1H FY 2025 US$20m Loss Reinforces Bearish Community Narratives

SEALSQ (LAES) just posted its FY 2025 first half numbers with revenue of roughly US$4.8 million and a basic EPS loss of US$0.17, against a trailing twelve month loss of US$0.38 per share on about US$11.0 million of revenue. Over the last three reported half year periods, revenue has moved between about US$4.8 million and US$6.2 million, while basic EPS losses ranged from US$0.17 to US$0.60. This has kept margins firmly in the red and put the focus squarely on how the business can turn growing...
NasdaqGM:PNBK
NasdaqGM:PNBKBanks

Patriot National Bancorp (PNBK) Quarterly Loss Narrows To US$0.02 EPS Challenging Persistent Bearish Narratives

Patriot National Bancorp (PNBK) just closed out FY 2025 with fourth quarter revenue of US$9.8 million and a basic EPS loss of US$0.02, alongside trailing twelve month revenue of US$28.1 million and a basic EPS loss of US$0.17. Over recent quarters the company has seen revenue move from US$4.7 million in Q2 2025 to US$7.6 million in Q3 2025 and then to US$9.8 million in Q4 2025. Quarterly basic EPS losses narrowed from US$0.21 in Q1 2025 to US$0.06 in Q2, US$0.03 in Q3 and US$0.02 in Q4...
NasdaqGS:VC
NasdaqGS:VCAuto Components

Is Visteon (VC) Rewriting Its Cockpit Electronics Story With Softer 2026 Guidance?

In recent days, Visteon reported mixed fourth-quarter results, with revenue exceeding expectations while earnings and full-year guidance, including softer 2026 revenue and EBITDA forecasts, fell short of analyst estimates. Analysts have largely maintained positive ratings despite trimming some expectations, highlighting investors’ focus on how Visteon balances growth in digital cockpit and connected car solutions with more cautious longer-term guidance. Next, we’ll examine how Visteon’s...
NasdaqCM:ANNA
NasdaqCM:ANNARenewable Energy

AleAnna (ANNA) Q3 Profit Of US$3.3 Million Tests Loss Making Narrative

AleAnna (NasdaqCM:ANNA) has just posted another quarter of rapid top line expansion, with Q3 FY 2025 revenue of about US$11.2 million and basic EPS of US$0.08, against a backdrop of very large revenue growth of 2,471.5% over the past year while remaining unprofitable on a trailing 12 month view. Over recent periods the company has seen revenue move from roughly US$0.6 million in Q3 FY 2024 to US$11.2 million in Q3 FY 2025, while trailing 12 month EPS across the last reported quarters stayed...
NYSE:RH
NYSE:RHSpecialty Retail

RH (RH) Earnings Rebound And Margin Improvement Challenge Cautious Leverage Narratives

RH (RH) has wrapped up FY 2026 with fourth quarter revenue of US$842.6 million and basic EPS of US$1.53, capping a twelve month run where EPS on a trailing basis reached US$6.65 on revenue of about US$3.4 billion alongside a 72.4% year over year earnings recovery after several years of declines. Over the past eight quarters, revenue has moved from US$812.4 million in Q4 FY 2025 to US$842.6 million in Q4 FY 2026. Over the same period, quarterly EPS has ranged between US$0.75 and US$2.76 and...
NYSE:CE
NYSE:CEChemicals

Celanese Shelf Registration Adds Flexibility While Valuation Appears Depressed

Celanese Corporation (NYSE:CE) has filed an omnibus shelf registration with regulators. The filing allows the company to offer common stock, preferred stock, and debt securities over time. This structure gives Celanese the ability to raise capital when market conditions and funding needs align. Celanese produces specialty materials and chemicals used across sectors such as automotive, construction, and consumer goods, so access to flexible funding can matter for large projects or potential...
NYSE:EFOR
NYSE:EFORIT

Quinnox Deal and Everforth Rebrand Could Be A Game Changer For ASGN (ASGN)

In its latest quarter, ASGN reported revenue and adjusted EBITDA margins ahead of expectations but missed EPS forecasts, while also outlining integration of the Quinnox acquisition and a rebranding to Everforth to consolidate its seven brands. This combination of earnings mixed with margin outperformance and a pivot toward higher-value consulting and unified branding could meaningfully reshape ASGN’s business mix and competitive positioning over time. We’ll now examine how ASGN’s Quinnox...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The data show durable efficacy across multiple clinical response thresholds and improvements in patient quality of life at 54 weeks. Safety results were consistent over the long term, supporting the overall benefit risk profile of povorcitinib in HS. This is the first publication of long-term pivotal data for povorcitinib in HS ahead of...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate

Oncolytics Biotech (NasdaqCM:ONCY) has completed its domestication from Canada to the United States. The company has relocated its headquarters to San Diego, with the move now effective. Oncolytics Biotech is now classified as a U.S. domestic issuer under the U.S. regulatory framework. The domestication is intended to support operational efficiencies and access to U.S. capital markets. For you as an investor, this shift touches on both regulation and capital access. Oncolytics Biotech is an...
NYSEAM:KULR
NYSEAM:KULRElectrical

KULR Technology Group (KULR) Q4 Loss Of US$44.3 Million Tests Bullish Growth Narratives

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...
NasdaqCM:FTLF
NasdaqCM:FTLFPersonal Products

FitLife Brands (FTLF) Margin Compression In FY 2025 Tests Bullish Growth Narratives

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...
NasdaqGS:CHKP
NasdaqGS:CHKPSoftware

Check Point Software Technologies (CHKP) Margin Expansion To 38.8% Tests Bearish EPS Decline Narrative

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...
NasdaqGS:DWSN
NasdaqGS:DWSNEnergy Services

Dawson Geophysical (DWSN) Returns To Quarterly Profit Challenging Volatility‑Focused Narratives

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

Silicon Motion Targets Auto Grade NAND To Balance AI And PC Cycles

Silicon Motion Technology (NasdaqGS:SIMO) is expanding its automotive grade NAND storage controller portfolio for connected and AI focused vehicles. The company is aligning products with automotive safety and cybersecurity standards such as AEC-Q100, ISO 26262, ISO 21434, and ASPICE Level 3. Its embedded storage solutions are being tailored for advanced driver-assistance systems and autonomous driving platforms. For readers following NasdaqGS:SIMO, this push into automotive storage sits on...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...